Announcements

2025

**November**
25/11/2025	2025 AGM Notice of Meeting
24/11/2025	2025 Annual Report

**October**
29/10/2025	BioDiem Shareholder Update

**August**
06/08/2025	BioDiem Update and EOFY 25 Information

**June**
26/06/2025	Change of Address for Registered Office and Principal Place of Business

**May**
20/05/2025	Half Yearly Financial Report

2024

**December**
03/12/2024	2024 AGM Results of Meeting
	2024 AGM Chair’s Address
	2024 AGM CEO Presentation

**November**
07/11/2024	Notice of Annual General Meeting and Proxy Form

**September**
09/09/2024	Results of General Meeting and 2016 CPS Meeting

**August**
15/08/2024	BioDiem Notice of General Meeting and Proxy Form

**July**
04/07/2024	BioDiem Update and EOFY information

**April**
22/04/2024	Half-year Financial Report
19/04/2024	Results of GM

**March**
26/03/2024	Notice of Meeting and Proxy Form

2023

**November**
30/11/2023	Results of Annual General Meeting
	CEO AGM 2023 Presentation
29/11/2023	Chairman’s Address
09/11/2023	2023 AGM Notice of Meeting
08/11/2023	2023 BioDiem Annual Report

**September**
01/09/2023	Opal capital raise for growth strategy – Information Memorandum
	Opal BioSciences Information Memorandum

**August**
17/08/2023	Change of Auditor
09/08/2023	BioDiem Ltd Board change
04/08/2023	Company Update and EOFY 2023 Information

**July**
18/07/2023	Opal Biosciences awarded Investment Attraction Fund grant by WA government

**June**
21/06/2023	Proposed acquisition of specialist formulation company Formulytica

**May**
17/05/2023	BioDiem Half Year Financial Report FY21

2022

**December**
20/12/2022	Chairman’s Address
	AGM CEO Presentation
	Results of AGM

**November**
24/11/2022	2022 BioDiem Annual Report
	Notice of AGM

**September**
30/09/2022	Exercise of Options

**August**
11/08/2022	EOFY 2022 Information

**March**
29/03/2022	BioDiem Board Changes

**February**
25/02/2022	New BioDiem Board Appointment

2021

**November**
30/11/2021	2021 AGM Chairman’s Address
	2021 AGM Results of Meeting
	2021 AGM Presentation
08/11/2021	Notice of Meeting
04/11/2021	2021 BioDiem Annual Report

**September**
22/09/2021	EOFY 2021 Information
08/09/2021	Board Changes

**July**
14/07/2021	Biotech Precinct Progress

**June**
30/06/2021	LAIV Success in China
11/06/2021	Extension to Closing Date of Opal Capital Raising
02/06/2021	Growth of Formulytica client base

**May**
07/05/2021	Share Application Form
	Accountant Certification
06/05/2021	Opal acquisition of Formulytica – Capital raising
	Opal Biosciences 2021 Information Memorandum
05/05/2021	Opal announces acquisition of specialist formulation company Formulytica

**April**
01/04/2021	BioDiem Half Year Report
	BioDiem Half Year Announcement

2020

**December**
01/12/2020	2020 AGM Presentation
	2020 AGM Chairman’s Address
	2020 AGM Results of Meeting

**October**
30/10/2020	Annual Report 30 June 2020
	2020 Notice of Annual General Meeting and Explanatory Statement and Proxy Form

**August**
25/08/2020	Launch of LAIV Flu vaccine in China

**July**
07/07/2020	BioDiem and Opal Update and EOFY information

**March**
27/03/2020	BioDiem Half-year Financial Report – 31 December 2019
	BioDiem Releases Half Year Results

**February**
28/02/2020	LAIV Influenza Vaccine Approved in China

2019

**November**
29/11/2019	2019 AGM Presentation
	2019 Chaiman’s Address
	2019 AGM Results

**October**
29/10/2019	BioDiem Notice of Meeting
28/10/2019	Annual Report 30 June 2019

**July**
12/07/2019	BioDiem and Opal Update \| EOFY information

**March**
20/03/2019	BioDiem Releases Half Year Results
	Half-year Financial Report – 31 December 2018

2018

**November**
27/11/2018	BioDiem 2018 AGM Chairman’s Address
	BioDiem AGM 2018 CEO Presentation
	BioDiem AGM 2018 Results of Meeting
08/11/2018	BioDiem 2018 Notice of Annual General Meeting and Explanatory Statement and Proxy Form
	Annual Report 30 June 2018

**August**
03/08/2018	Company Update and EOFY 2018 Information

**July**
19/07/2018	Opal Information Memorandum Announcement
	Opal Information Memorandum Document

**May**
01/05/2018	BioDiem receives Innovation Connections grant for Opal work

**April**
09/04/2018	BioDiem Limited – Half-year Financial Report 31 Dec 2017
	BioDiem Limited – Half-year Results
	Opal Biosciences Limited – Half-year Financial Report 31 Dec 2017
	Opal BioSciences – Half-year Results

**March**
01/03/2018	2018 \| Opal: Completion of Placement and Board change

**February**
14/02/2018	Patent grant in US and Europe

2017

**November**
20/11/2017	2017 BioDiem AGM CEO Presentation
	Results of 2017 BioDiem AGM
	2017 BioDiem AGM Chairman’s address
10/11/2017	Receipt of 2017 Income Tax Return Refund

**October**
20/10/2017	BioDiem Annual Report 2017
	BioDiem Notice of Annual General Meeting – Explanatory Statement

**July**
10/07/2017	BioDiem – OPAL Update and EOFY information

**May**
22/05/2017	Receipt of 2016 Income Tax Return Refund

**March**
17/03/2017	BioDiem Releases Half Year Results

2016

**October**
19/10/2016	2016 BioDiem Results of Meeting
	2016 Chairman’s Address

**September**
19/09/2016	BioDiem Annual Report 2016
	BioDiem Notice of Annual General Meeting and Proxy form 2016

**August**
10/08/2016	Completion of Entitlement Offer and Issue of Convertible Preference Shares

**June**
14/06/2016	BioDiem Entitlement Offer Replacement Prospectus
	Non-renounceable pro rata Entitlement Offer

**May**
11/05/2016	Results of General Meeting

**April**
13/04/2016	BDM-I Presentation at European Clinical Conference
08/04/2016	Notice of General Meeting with Proxy

**March**
31/03/2016	Influenza Vaccine Clinical Trial commences in China
	BioDiem Releases Half Year Results

**February**
26/02/2016	BioDiem/Opal Biosciences Investor Presentation at Wholesale Investor

**January**
22/01/2016	Appointment of Prof Li to the BioDiem Board
	Completion of Non-renounceable Entitlement Offer and Issue of Entitlement and Shortfall Shares
	Share Trading Contact Information

2015

**December**
23/12/2015	Income Tax Return Refund
22/12/2015	Rights Issue Closure and Results
11/12/2015	Further US patent granted for Opal
04/12/2015	BioDiem is presented at Wholesale Investor, Sydney

**November**
27/11/2015	BioDiem Rights Issue
	BioDiem Entitlement Offer Prospectus
25/11/2015	BioDiem is presented at Wholesale Investor, Melbourne
06/11/2015	New European patents for Opal Biosciences antimicrobial, BDM-I

**October**
21/10/2015	Nasovac-S WHO PreQualification Certification
19/10/2015	2015 Results of Meeting
	2015 Chairman’s Address to AGM
	2015 AGM CEO Address
	AGM 2015 Presentation

**September**
24/09/2015	Chinese FDA gives approval to start LAIV vaccine clinical trials
17/09/2015	BioDiem Notice of Annual General Meeting and Proxy form 2015
	BioDiem Annual Report 2015

**August**
26/08/2015	Opal Update
07/08/2015	Shareholder Update

**July**
16/07/2015	Opal’s technology presented at the Australian Society for Microbiology Annual Meeting
10/07/2015	Successful grant for BDM-I – Griffith University
07/07/2015	Results of General Meeting

**June**
17/06/2015	Opal Biosciences’ anti-infective technology profiled at 2015 BIO International Convention
05/06/2015	BioDiem Shareholder Update: Opal Biosciences Ltd.

**May**
14/05/2015	May 2015 Shareholder Update

**March**
24/03/2015	Board Announcement – Don Brooks
16/03/2015	BioDiem Half Year Financial Report

**February**
23/02/2015	Notification of exercise of (8 cent) BioDiem options

**January**
30/01/2015	Letter to BioDiem option holders
	BioDiem Update
06/01/2015	Notice of extension of exercise period for BioDiem options to 13th February 2015

2014

**December**
24/12/2014	New Japanese patent for antimicrobial BDM-I
	Professor Arthur Li directorship
05/12/2014	BioDiem CEO appointed Chairman of Ausbiotech
	Wholesale Investor’s Sydney Capital Showcase and Australia Biotech Invest, Melbourne.
02/12/2014	Letter to Optionholders – Upcoming Expiry of 8 cent Options
	December 2014 newsletter

**November**
10/11/2014	Wholesale Investor – Singapore Capital Expo and Small Cap Showcase Presentation
07/11/2014	Notification of 8 cent Options Expiring 31 December 2014 with attached form

**October**
23/10/2014	2014 AGM Chairman’s address
	2014 BioDiem AGM CEO presentation
	2014 Results of Meeting

**September**
30/09/2014	Annual Report 2014
	BioDiem Notice of Annual General Meeting and Proxy form 2014
15/09/2014	BioDiem Full Year Financial Results

**June**
23/06/2014	ALS Investment Showcase San Francisco presentation 2014

**May**
29/05/2014	Griffith University’s Industry Fund collaborates in BDM-I screening

**April**
30/04/2014	Completion of Non-renounceable Entitlement Offer and Issue of Entitlement and Shortfall Shares
	BDM-I antimicrobial – mechanism of action investigation
23/04/2014	Non-Renounceable Entitlement Offer – Closure, Acceptances and Shortfall
10/04/2014	BioDiem Rights Issue Update.
09/04/2014	BioDiem supplementary prospectus

**March**
20/03/2014	Receipt of R&D Tax incentive payment
18/03/2014	Rights Issue – Replacement Prospectus
	BioDiem Replacement Prospectus
12/03/2014	BioDiem Limited-Half-year Financial Report
04/03/2014	BioDiem Prospectus Update

**February**
24/02/2014	BioDiem Rights Issue
	BioDiem Ltd prospectus
18/02/2014	Seasonal influenza vaccine using BioDiem’s technology approved for sale in India

2013

**December**
16/12/2013	Receipt of 2012 Income Tax Return Refund
12/12/2013	Shareholder Update – Delisting and New Issuer Sponsored Holding Statements
05/12/2013	Publication of Research in Journal of Virology

**November**
15/11/2013	BioDiem removal from ASX official list
07/11/2013	Suspension from Official Quotation 8 November, 2013

**October**
30/10/2013	Appendix 4C
28/10/2013	Australia Biotech Invest Presentation 2013
25/10/2013	Change of Principal Place of Business and Registered Office
24/10/2013	China Presentation of BioDiem’s Liver Treatment Technology
08/10/2013	2013 Results of Meeting
	AGM CEO Presentation
	Chairmans Address to AGM

**September**
24/09/2013	BDM WI Capital Showcase Presentation
16/09/2013	BioDiem’s BDM-I presented at international conference
09/09/2013	Appendix 3Y Change of director’s interest notice
06/09/2013	Appendix 3Y Change of Director’s interest notice
	BioDiem Notice of Annual General Meeting and Proxy Form 2013
	Chairmans Letter AGM 2013
	Annual Report 2013

**August**
30/08/2013	Proposed Delisting from ASX
27/08/2013	Appendix 4E and Statutory Accounts
23/08/2013	BDM-I Third US patent

**July**
31/07/2013	Appendix 4C
23/07/2013	BDM Presentation to Shareholders Sydney
22/07/2013	Proof of Principle shown in liver disease vaccine program
11/07/2013	Griffith Uni study enhances BioDiem’s antimicrobial program
05/07/2013	BDM Expiry Unlisted Options

**June**
19/06/2013	BioDiem’s Asia Biotech Invest 2013 video presentation
04/06/2013	Asia Biotech Investor presentation 2013

**May**
22/05/2013	New Japanese protozal patent for BDM-I
10/05/2013	BDM-I progress in NIH Research Program as Fungal Infection Treatment

**April**
30/04/2013	Appendix 4C
19/04/2013	ALSIS Investment Showcase NY presentation April 2013
05/04/2013	Van Leeuwenhoeck Research publishes updated analyst report
	Van Leeuwenhoeck Research Full Report

**March**
20/03/2013	BioPharma Asia Presentation March 2013

**February**
21/02/2013	Additional Antimicrobial Patent Granted in China
	BioDiem Half Yearly Report and Accounts
14/02/2013	BioDiem extends co-operative agreement with USAMRIID
	Investor Presentation
12/02/2013	Chinese vaccine partner pays annual license fee early
08/02/2013	Progress to POC testing of BDMI effect against parasites
07/02/2013	Change of Registered Office
01/02/2013	BioDiem’s antimicrobial continues in US NIH Research Program

**January**
31/01/2013	Appendix 4C – quarterly
15/01/2013	BioDiem Update

2012

**December**
12/12/2012	SII progresses international plans for BioDiem vaccines

**November**
21/11/2012	Japanese Patent Office to grant BioDiem new patent for BDM-I antimicrobia
20/11/2012	Wholesale Investor Emerging Company Showcase presentation
15/11/2012	Change to Company Secretary
08/11/2012	BDM partners with Griffith University to enhance antimicrobial drug
02/11/2012	Australasian Life Science Investment Summit Presentation
01/11/2012	Appendix 3B
	Replacement Prospectus

**October**
24/10/2012	Appendix 4C – quarterly
	Extension to closing date for Renounceable Rights Issue
18/10/2012	BDM-I Program Update
15/10/2012	Amendment to Notice of Annual General Meeting
12/10/2012	Annual Report to shareholders
04/10/2012	Letter to Shareholders
01/10/2012	Renounceable Issue Prospectus

**September**
28/09/2012	Full Year Statutory Accounts
	BioDiem Investor Presentation
	Appendix 3B
	BioDiem Renounceable Rights Issue

**August**
31/08/2012	Preliminary Final Report
08/08/2012	Successful growth of BioDiem’s Virus in VIVALIS EB66 Cell Line
	BioDiem granted European patent for BDM-I antimicrobial

**July**
27/07/2012	Appendix 4C – quarterly
23/07/2012	BDM presents findings at international eye research meeting
19/07/2012	BioDiem signs seed development research agreement with RMIT
03/07/2012	BioDiem Company Update

**June**
29/06/2012	Letter to Shareholders
26/06/2012	BioDiem secures rights to novel Hepatitis technology
25/06/2012	BioDiem signs Dengue Fever agreement with ANU
18/06/2012	Australian Life Science Investment Showcase
06/06/2012	ANU to grant BioDiem exclusive license for novel technology

**May**
30/05/2012	BioDiem partners with Foundation Fighting Blindness
10/05/2012	BioDiem Option Expiry Notice
09/05/2012	BioDiem LAIV to be tested in French proprietary cell line
08/05/2012	BioDiem receives licence fees for LAIV influenza vaccine
03/05/2012	BDM-I patent position strengthened with new US patent

**April**
30/04/2012	Appendix 4C – quarterly
23/04/2012	April 2012 Shareholder Update

**February**
29/02/2012	Half Year Report and Accounts
09/02/2012	BioDiem Licenses LAIV Technology to Changchun BCHT Biotechnology

**January**
24/01/2012	Appendix 4C – quarterly

**December**
//	2017 AGM Chairman’s address
	2017 BioDiem AGM Results
	BioDiem 2017 AGM CEO Presentation
	BioDiem 2017 AGM Chairman’s address
	2017 BioDiem AGM Chair address
	BioDiem Update and EOFY information
	BioDiem Board Change
	2024 Annual Report
	Half Year Financial Report

Rights Issue Closure and Results Announcement - (FINAL) For ASX releases in prior years to those listed above, kindly visit the ASX Page and key in the code BDM.